{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T12:26:16Z","timestamp":1788006376665,"version":"build-2784847793"},"reference-count":63,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: The therapeutic landscape of advanced or metastatic urothelial carcinoma (UC) has shifted from platinum chemotherapy to precision immuno-oncology. Immune checkpoint inhibitors (ICIs)\u2014pembrolizumab, nivolumab, and avelumab\u2014show efficacy across platinum-refractory, maintenance, and adjuvant settings, yet benefit is limited to subsets, underscoring the need for biomarkers. Antibody\u2013drug conjugates (ADCs), notably enfortumab vedotin(EV), and targeted agents such as FGFR inhibitors further expand options. This review synthesizes current evidence and emerging paradigms to guide combinations and sequencing. Methods: We performed a narrative synthesis of peer-reviewed trials (emphasizing pivotal phase III studies), key translational investigations, and contemporary guidelines on ICIs, ADCs, HER2-directed therapies, FGFR inhibitors, molecular subtyping, and genomic profiling in UC, integrating efficacy signals, biomarker associations, and practical implications for sequencing. Results: ICIs now occupy multiple settings, but heterogeneous benefit highlights the importance of molecularly informed selection. EV alone and with pembrolizumab has produced unprecedented first-line activity, prompting a strategic shift. Molecular subtyping and genomic profiling delineate phenotypes with variable immune responsiveness and targetable vulnerabilities, enabling rational combinations and refined sequencing. Ongoing trials are evaluating next-generation ADCs, HER2-directed approaches, and dual checkpoint blockade to achieve durable, personalized disease control. Conclusions: Management of locally advanced or metastatic UC is converging on precision immuno-oncology, wherein biomarker-driven selection, molecular subtyping, and thoughtful sequencing of ICIs, ADCs, and targeted agents are central to optimizing outcomes. Active trials and translational advances are expected to refine personalized strategies and embed molecular guidance into routine care.<\/jats:p>","DOI":"10.3390\/cancers17203367","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:44:10Z","timestamp":1760957050000},"page":"3367","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Navigating Therapeutic Landscapes in Urothelial Cancer: From Chemotherapy to Precision Immuno-Oncology"],"prefix":"10.3390","volume":"17","author":[{"given":"Takatoshi","family":"Somoto","sequence":"first","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9423-7361","authenticated-orcid":false,"given":"Takanobu","family":"Utsumi","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ishitsuka","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Noro","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Iijima","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Sugizaki","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-2490","authenticated-orcid":false,"given":"Naoto","family":"Kamiya","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5838-114X","authenticated-orcid":false,"given":"Hiroyoshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Bilim, V., Kuroki, H., Shirono, Y., Murata, M., Hiruma, K., and Tomita, Y. (2022). Advanced bladder cancer: Changing the treatment landscape. J. Pers. Med., 12.","DOI":"10.3390\/jpm12101745"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Escobar, D., Wang, C., Suboc, N., D\u2019souza, A., and Tulpule, V. (2025). Diagnosis and management of upper tract urothelial carcinoma: A review. Cancers, 17.","DOI":"10.3390\/cancers17152467"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.3390\/curroncol28060428","article-title":"Management of localized muscle-invasive bladder cancer from a multidisciplinary perspective: Current position of the Spanish Oncology Genitourinary (SOGUG) Working Group","volume":"28","author":"Maroto","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_7","first-page":"404","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7","article-title":"Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse","volume":"64","author":"Sternberg","year":"1989","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"Hansen","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Godlewski, D., Czech, S., Szpara, J., Bartusik-Aebisher, D., and Aebisher, D. (2025). A narrative review of current advances and future changes regarding bladder cancer treatment. Uro, 5.","DOI":"10.3390\/uro5020011"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Dobruch, J., and Oszczud\u0142owski, M. (2021). Bladder cancer: Current challenges and future directions. Medicina, 57.","DOI":"10.3390\/medicina57080749"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2023 guidelines","volume":"85","author":"Witjes","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): A phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"ref_18","first-page":"2254","article-title":"Escalated M-VAC chemotherapy and recombinant human GM-CSF in patients with advanced urothelial tract tumors","volume":"11","author":"Sternberg","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","article-title":"Randomized phase III trial of high-dose-intensity MVAC chemotherapy and recombinant human GM-CSF versus classic MVAC in advanced urothelial tract tumors: EORTC Protocol No","volume":"19","author":"Sternberg","year":"2001","journal-title":"30924. J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose-dense MVAC or gemcitabine\u2013cisplatin as perioperative chemotherapy for nonmetastatic muscle-invasive bladder cancer: Results of the GETUG-AFU V05 VESPER trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Roviello, G., Catalano, M., Santi, R., Palmieri, V.E., Vannini, G., Galli, I.C., Buttitta, E., Villari, D., Rossi, V., and Nesi, G. (2021). Immune checkpoint inhibitors in urothelial bladder cancer: State of the art and future perspectives. Cancers, 13.","DOI":"10.3390\/cancers13174411"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yajima, S., and Masuda, H. (2025). Immune checkpoint inhibitors and antibody\u2013drug conjugates in urothelial carcinoma: Current landscape and future directions. Cancers, 17.","DOI":"10.3390\/cancers17091594"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1634\/theoncologist.2018-0084","article-title":"FDA approval summary: Atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy","volume":"24","author":"Suzman","year":"2019","journal-title":"Oncologist"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(23)00540-5","article-title":"Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): Final overall survival analysis of a randomized, controlled, phase 3 study","volume":"25","author":"Grande","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): A randomized, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2023.01.016","article-title":"Disease-free survival analysis for patients with high-risk muscle-invasive urothelial carcinoma from the randomized CheckMate 274 trial by PD-L1 combined positive score and tumor cell score","volume":"83","author":"Galsky","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): A multicentre, open-label, randomized, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdz296","article-title":"EAU\u2013ESMO consensus statements on the management of advanced and variant bladder cancer: An international collaborative multi-stakeholder effort under the auspices of the EAU and ESMO Guidelines Committees","volume":"30","author":"Horwich","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated Overall Survival by Circulating Tumor DNA Status from IMvigor010: Adjuvant Atezolizumab versus Observation","volume":"85","author":"Powles","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Xiao, J., Caliri, A.W., Duex, J.E., and Theodorescu, D. (2021). Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling. Cancers, 13.","DOI":"10.3390\/cancers13194891"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Mohanty, S.K., Lobo, A., Mishra, S.K., and Cheng, L. (2023). Precision Medicine in Bladder Cancer: Present Challenges and Future Directions. J. Pers. Med., 13.","DOI":"10.3390\/jpm13050756"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.euo.2024.01.013","article-title":"Profiling FGFR3 Expression Based on the Immune Microenvironment in Upper Tract Urothelial Carcinoma","volume":"7","author":"Shigeta","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper Tract Urothelial Carcinoma Has a Luminal\u2013Papillary T-Cell\u2013Depleted Contexture and Activated FGFR3 Signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2147\/CMAR.S445529","article-title":"Upper Tract Urothelial Carcinoma (UTUC): Prevalence, Impact and Management Challenge","volume":"16","author":"Nally","year":"2024","journal-title":"Cancer Manag. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e169241","DOI":"10.1172\/JCI169241","article-title":"FGFR Inhibition Augments Anti-PD-1 Efficacy in Murine FGFR3-Mutant Bladder Cancer by Abrogating Immunosuppression","volume":"134","author":"Okato","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eururo.2017.03.010","article-title":"Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset","volume":"72","author":"Choi","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/his.15287","article-title":"Molecular Heterogeneity among Conventional and Subtype Histology of Urothelial Carcinoma: A Review","volume":"85","author":"Lobo","year":"2024","journal-title":"Histopathology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of Molecular Subtypes in Muscle-Invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.annonc.2024.09.008","article-title":"Basal\/Squamous and Mixed Subtype Bladder Cancers Present Poor Outcomes after Neoadjuvant Chemotherapy in the VESPER Trial","volume":"36","author":"Groeneveld","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41467-022-29441-y","article-title":"Predictive Biomarkers for Survival Benefit with Ramucirumab in Urothelial Cancer in the RANGE Trial","volume":"13","author":"Powles","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13000-023-01295-y","article-title":"Immunohistochemical-Based Molecular Subtypes of Muscle-Invasive Bladder Cancer: Association with HER2 and EGFR Alterations, Neoadjuvant Chemotherapy Response and Survival","volume":"18","author":"Helal","year":"2023","journal-title":"Diagn. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e178540","DOI":"10.1172\/JCI178540","article-title":"Epigenetic Regulation of Tumor Immunity","volume":"134","author":"Pang","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Yang, L., Gu, X., Yu, J., Ge, S., and Fan, X. (2021). Oncolytic Virotherapy: From Bench to Bedside. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.790150"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100738","DOI":"10.1016\/j.tranon.2019.12.010","article-title":"Resistance to Checkpoint Inhibition in Cancer Immunotherapy","volume":"13","author":"Barrueto","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., and Zhao, X. (2022). Mechanisms of Tumor Resistance to Immune Checkpoint Blockade and Combination Strategies to Overcome Resistance. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.915094"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1002307","DOI":"10.37349\/etat.2025.1002307","article-title":"Strategies to Overcome Resistance to Enfortumab Vedotin and Pembrolizumab for Urothelial Carcinoma","volume":"6","author":"Jang","year":"2025","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary Resistance to PD-1 Blockade Mediated by JAK1\/2 Mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Han, X., Zhang, J., Li, W., Huang, X., Wang, X., Wang, B., Gao, L., and Chen, H. (2025). The Role of B2M in Cancer Immunotherapy Resistance: Function, Mechanism, and Reversal Strategies. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1512509"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF-\u03b2 Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Khoury, R., Saleh, K., Khalife, N., Saleh, M., Chahine, C., Ibrahim, R., and Lecesne, A. (2023). Mechanisms of Resistance to Antibody-Drug Conjugates. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119674"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.gendis.2018.05.003","article-title":"Immunogenic Effects of Chemotherapy-Induced Tumor Cell Death","volume":"5","author":"Wang","year":"2018","journal-title":"Genes Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus Gemcitabine\u2013Cisplatin in Advanced Urothelial Carcinoma","volume":"389","author":"Sonpavde","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Evmorfopoulos, K., Mitrakas, L., Karathanasis, A., Zachos, I., Tzortzis, V., and Vlachostergios, P.J. (2023). Upper Tract Urothelial Carcinoma: A Rare Malignancy with Distinct Immuno-Genomic Features in the Era of Precision-Based Therapies. Biomedicines, 11.","DOI":"10.3390\/biomedicines11071775"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Fahey, C.C., Clark-Garvey, S., Porten, S., Kamat, A.M., Flaig, T.W., Taylor, J.A., Kim, W.Y., and Milowsky, M.I. (2025). Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32050278"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1470-2045(25)00158-5","article-title":"Enfortumab Vedotin plus Pembrolizumab versus Chemotherapy in Untreated Advanced Urothelial Cancer (EV-302): Patient-Reported Outcomes","volume":"26","author":"Gupta","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab Vedotin plus Pembrolizumab in Untreated Advanced Urothelial Carcinoma: 2.5-Year Median Follow-Up of EV-302\/KEYNOTE-A39","volume":"36","author":"Powles","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1080\/14796694.2025.2535280","article-title":"SGNDV-001: Disitamab Vedotin with Pembrolizumab in HER2-Expressing Advanced Urothelial Carcinoma","volume":"21","author":"Powles","year":"2025","journal-title":"Future Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/20\/3367\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:59:44Z","timestamp":1760957984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/20\/3367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":63,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17203367"],"URL":"https:\/\/doi.org\/10.3390\/cancers17203367","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]}}}